Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: A multicentre retrolective cohort study

Diabetologia

Volumn 46, Issue 12, 2003, Pages 1611-1617

  Martin, S ^a   Kolb, H ^a   Beuth, J ^b   Van Leendert, R ^b   Schneider, B ^c   Scherbaum, W A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Body mass index; Glibenclamide; Glimepiride; Retrolective; Type 2 diabetes

Indexed keywords

CHOLESTEROL; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT DISORDER; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0346846766     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-003-1238-x     Document Type: Article

References (24)

1. Tremble JM, Donaldson D (1999) Is continued weight gain inevitable in type 2 diabetes mellitus? J R Soc Health 119:235-239
2. Williams KV, Kelley DE (2000) Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes. Diabetes Obes Metab 2:121-129.
3. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853.
4. Scholz G, Schneider K, Knirsch W, Becker G (2001) Efficacy and tolerability of glimepiride in daily practice. Clin Drug Invest 21:597-604
5. Weitgasser R, Lechleitner M, Luger A, Klinger A (2003) Effects of glimepiride on HbA1c and body weight in Type 2 diabetes: results of a 1.5 year follow-up study. Diabetes Res Clin Pract 61:13-19
6. Müller G, Satoh Y, Geisen K (1995) Extrapancreatic effects of sulfonylureas - a comparison between glimepiride and conventional sulfonylureas. Diabetes Res and Clin Pract 28 [Suppl]:S115-S137
7. Müller G (2000) The molecular mechanism of the insulin-mimetic/ sensitizing activity of the antidiabetic sulfonylurea drug Amaryl. Molecular Medicine 6:907-933
8. Holstein A, Plaschke A, Hammer C, Egberts E-H (2003) Characteristics and time course of severe glimepiride-versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol 59:91-97
9. Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J (2002) Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 25:1607-1611
10. Overkamp D, Volk A, Maerker E, Heide PE, Wahl HG, Rett K, et al. (2002) Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care 25:2065-2073
11. Sacks H, Chalmers TC, Smith H Jr (1982) Randomized versus historical controls for clinical trials. Am J Med 72:233-240
12. Kunz R, Oxman AD (1998) The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. BMJ 317:1185-1190
13. Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. N Engl J Med 342:1878-1886
14. Concato J, Shah N, Horwitz RI (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342:1887-1892
15. Horwitz RI, Viscoli CM, Clemens JD, Sadock RT (1990) Developing improved observational methods for evaluating therapeutic effectiveness. Am J Med 89:630-638
16. Rubin DB (1997) Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757-763
17. Schneider B (2001) Analysis of therapeutic efficacy in observational cohort studies. Cancer Chemother Pharmacol 47 [Suppl]:S35-37
18. Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55
19. Draeger K, Wernicke-Panten K, Lomp HJ, Schuler E, Rosskamp R (1996) Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 28:419-425
20. Müller G, Hartz D, Punter J, Okonomopulos R, Kramer W (1994) Differential interaction of glimepiride and glibenclamide with the beta cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta 1191: 267-277
21. Sigal RJ, El-Hashimy M, Martin BC, Soeldner JS, Krolewski AS, Warram JH (1997) Acute postchallenge hyperinsulinemia predicts weight gain: a prospective study. Diabetes 46:1025-1029
22. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S (2001) Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 50:1457-1461
23. Rydberg T, Jonsson A, Roder M, Melander A (1994) Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 17:1026-1030
24. Badian M, Korn A, Lehr K-H, Malerczyk V, Waldhausl W (1996) Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration. Drug Metabol Drug Interact 13:69-85